



SUPPLEMENTAL FIGURE 1

Representative example of the blood clearance of ^{68}Ga -DOTA-exendin-4 and ^{111}In -DOTA-exendin-4, after blood sampling at 2, 5, 15, 30, 60, 120, and 180 min (additional sampling at 300 min, only ^{111}In -DOTA-exendin-4) after injection of the radiotracers, in patient 1. The results were analyzed by GraphPad Prism software as a 2-phase exponential decay. The half-lives of ^{68}Ga -DOTA-exendin-4 were estimated to be 11 min (α phase) and 40 min (β phase), whereas longer half-lives of 17 min (α phase) and 90 min (β phase) were estimated for ^{111}In -DOTA-exendin-4. Values were not decay-corrected.